The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase II study of first-line everolimus plus bevacizumab (E+B) versus interferon α-2a plus bevacizumab (I+B) in patients (pts) with metastatic renal cell carcinoma (mRCC): Record-2 final overall survival (OS) and safety results.
Alain Ravaud
Consultant or Advisory Role - Bayer Schering Pharma; Dendreon; GlaxoSmithKline; Novartis; Pfizer
Research Funding - Novartis; Pfizer; Roche
Carlos H. Barrios
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Boris Y. Alekseev
No relevant relationships to disclose
Miah Hiang Tay
Honoraria - Novartis
Sanjiv S. Agarwala
No relevant relationships to disclose
Suayib Yalcin
No relevant relationships to disclose
Chia-Chi Lin
No relevant relationships to disclose
Michail Shkolnik
No relevant relationships to disclose
Vsevolod Matveev
No relevant relationships to disclose
Ozlem Anak
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Sven Gogov
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Diana Pelov
Employment or Leadership Position - Novartis
Anne-Laure Louveau
Employment or Leadership Position - Novartis
Alexandra Vaury
Employment or Leadership Position - Novartis
Bohuslav Melichar
Consultant or Advisory Role - Novartis; Roche
Honoraria - Novartis; Pfizer; Roche